Table 2 Algorithms (principal and alternative) to identify people receiving care for chronic HCV infection from the French National Health Data System
Principal algorithm | Alternative algorithm | ||
|---|---|---|---|
Items | Definitions | Modifications compared with principal algorithm | |
AT LEAST ONE MAJOR CRITERION DURING THE YEAR AMONG THE FOLLOWING: | |||
HCV genotyping | ≥ 1 reimbursement | ||
HCV antiviral treatment | ≥ 1 reimbursement for pegylated interferon and ribavirin (with at least one common delivery date) or for first or second generation DAAs | ||
HCV RNA quantitative PCR | ≥ 3 reimbursements | ≥ 2 | |
Hospitalization with a principal or related diagnosis of chronic hepatitis C | ≥ 1 hospitalization with a principal or related diagnosis of chronic hepatitis C in medicine, surgery or obstetric services | ||
Long-term disease (LTD) registration for chronic hepatitis C (“incident patients”) | New LTD registrations for chronic hepatitis C | ||
OR | |||
BOTH THE INTERMEDIATE CRITERION DURING THE YEAR: | |||
HCV RNA quantitative PCR | 2 reimbursements | 1 | |
AND AT LEAST ONE MINOR CRITERION DURING THE YEAR AMONG THE FOLLOWING: | ≥ 2 | ||
Liver fibrosis assessment | ≥ 1 reimbursement for liver biopsy, fibrosis, liver stiffness measurement or blood biomarkers | ||
Long-term disease registration for chronic hepatitis C (“prevalent patients”) | Patients registered with LTD status, excluding those admitted during the year | ||
Hospitalization with an associated diagnosis of chronic hepatitis C | ≥ 1 hospitalization with an associated diagnosis of chronic hepatitis C in medicine, surgery or obstetric services | ||